Effect of Citicoline on liver fat content in mice fed a high-fat diet, an experimental study

Author:

Sharifi Amrollah1,Jarvand Zahra2,Ghasemi Shima3

Affiliation:

1. Golestan University of Medical Sciences

2. Zahra Jarvand, Golestan University of Medical Sciences

3. Shima Ghasemi, Golestan University of Medical Sciences

Abstract

Abstract Citicoline may have a beneficial role in the protection of hepatocytes because of its role in reducing oxidative stress and its choline part role in the production of VLDL. Choline deficiency leads to liver fat accumulation, which is treated by supplying choline. The purpose of this study was to investigate the hypothesis, of whether the administration of citicoline, the precursor of choline, in mice on a high-fat diet is effective in reducing the amounts of liver fat content. Twenty-four male C57BL/6 mice, after 2 weeks on a high-fat (HF) diet, were randomly assigned to the 4 groups. Control: HF diet mice without intervention, dose 1: HF diet mice with a dose of 10 mg/kg Citicoline, dose 2: HF diet mice with an amount of 20 mg/kg citicoline, and dose 3: HF diet mice with an amount of 30 mg/kg Citicoline. After 8 weeks, the mice’s body weights, liver weights, liver dry weights, and liver fat percentages were measured. All the aspects of ARRIVE and PREPARE guidelines were considered. The differences in liver fat % between the control, dose 1, and dose 2 groups were not statistically meaningful (8.37 ± 0.39, 8.08 ± 0.65, 7.63 ± 0.55, and 7.34 ± 0.65 % for control, dose 1, dose 2, and dose 3 groups respectively; p for ANOVA test: 0.0381). A posthoc Tukey test showed that liver fat % was statistically different only between the control and dose 3 groups (mean diff: 1.03, 95%CI: 0.05 to 2.0). The liver total weight and liver dry weight were not different between the groups (p= 0.94, and p= 0.66 respectively). The intervention did not affect the mice's body weights. It seems that citicoline can be considered as a dietary supplement in the treatment of fatty liver. RCT studies are suggested to test this hypothesis.

Publisher

Research Square Platform LLC

Reference38 articles.

1. NAFLD: a multisystem disease;Byrne CD;Journal of hepatology,2015

2. Non-alcoholic fatty liver disease;Powell EE;The Lancet,2021

3. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review;Younossi ZM;Hepatology,2023

4. Mechanisms of NAFLD development and therapeutic strategies;Friedman SL;Nature medicine,2018

5. Management of NAFLD: a stage-based approach;Rinella ME;Nature reviews Gastroenterology & hepatology,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3